Loading…
← CockpitCompetitor Analysis › MNPR Monopar Therapeutics IncOpen in the cockpit ↗

Monopar Therapeutics IncMNPRCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum weak 32
Mkt cap
$479M
US dollars, full cap
Free float
59%
of shares outstanding
$/day
$11.1M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 13.2%
Hurdle
n/a
no reverse DCF
Next earnings
127 days
25 Mar 2027
Close · USD$70.75
1D-0.4%
1W-1.4%
1M-4.7%
3M-36.2%
6M+8.9%
YTD+8.3%
1Y-7.4%
ATR %6.7%
Beta1.31
52w lowhigh43.3% off high

What Monopar Therapeutics does

Employees: 22

Monopar Therapeutics at a glance

Size Monopar Therapeutics (MNPR) is a United States Health Care company (Biotechnology) with a market value of $479M, the 2698th largest of 3,085 United States companies the cockpit tracks. Shares closed at $70.75 on 18 Nov 2026.

Performance Over six months the shares gained 8.9%, against -14.1% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 18 in its peer set.

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026MNPR 113Peer median 84
Six months, rebased to 100: Monopar Therapeutics against the median of its 20 peers (local-currency closes).

Monopar Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit$0$0$0$0$0
EBITDA-$25.5M-$16.7M-$16.2M-$8.83M-$10.5M
Net income-$20.6M-$13.7M-$15.6M-$8.40M-$10.5M
Free cash flow-$16.3M-$12.2M-$6.40M-$7.86M-$7.23M
Capital expenditure$0$0$0$0$0
Total debt$199,806$154,920$0$0$56,990

Quarterly statements and history in the cockpit →

Monopar Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%NGNE4147CBIO6586FENC603255KMDA688247DMAC300858STTK041960VLA1151806589MNPR6-month return →1-month return →
Up and to the right = strong over both horizons. Monopar Therapeutics is the large dot.

Monopar Therapeutics competitors and peer comparison

How Monopar Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Monopar Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureMNPRPeer medianRank in peer set
1-month return-4.7%-11.1%7th highest of 21
6-month return+8.9%-14.1%6th highest of 18
Distance from 52-week high-43.3%-46.1%10th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Monopar Therapeutics MNPRUnited States$479M+9%n/an/an/an/an/a
Neurogene NGNEUnited States$479M-14%-100%n/an/an/an/a
TaiMed Biologics 4147.TWOTaiwan$480M+19%+7%-31%22.7×n/an/a
Crescent Biopharma CBIOUnited States$482M-34%n/a-1,217%13.3×n/an/a
CHO Pharma 6586.TWOTaiwan$488M+24%-47%-17,694%8,281.1×n/an/a
Fennec Pharmaceuticals FENCUnited States$471M+37%+71%5%6.4×58.8%+204.7%
TenNor Therapeutics Suzhou 6872.HKHong Kong$470Mn/an/an/an/an/an/a
Liaoning Dingjide Petrochemical 603255.SSChina$490M-24%+70%5%5.2×n/an/a
Kamada KMDAUnited States$465M+3%+5%15%2.0×5.0%+6.5%
Sinotherapeutics 688247.SSChina$494M-19%-17%0%6.2×29.4%+7.0%
DiaMedica Therapeutics DMACUnited States$463M+50%n/an/an/an/an/a
HanchorBio 7827.TWTaiwan$462Mn/an/a-4,673%509.6×n/an/a
Beijing Scitop Bio-Tech 300858.SZChina$501M-28%+4%8%7.5×n/an/a
Shattuck Labs STTKUnited States$455M-28%-100%n/an/an/an/a
Komipharm International 041960.KSSouth Korea$454M-2%-6%-1%11.8×n/an/a
Valneva VLA.PAFrance$508M-6%-27%-87%3.9×n/an/a
Qurient 115180.KSSouth Korea$452M-56%-14%-512%84.4×n/an/a
LongBio Pharma (Suzhou) 1779.HKHong Kong$510Mn/an/an/an/an/an/a
EirGenix 6589.TWTaiwan$444M+15%+58%-51%9.9×n/an/a
Beijing Bohui Innovation Biotechnology 300318.SZChina$518M-20%-1%-13%6.2×n/an/a
Arvinas ARVNUnited States$443M-26%-12%-10%n/an/an/a

Questions

Which companies are Monopar Therapeutics's closest peers?
The cockpit's peer set: Neurogene (NGNE), TaiMed Biologics (4147.TWO), Crescent Biopharma (CBIO), CHO Pharma (6586.TWO), Fennec Pharmaceuticals (FENC), TenNor Therapeutics Suzhou (6872.HK), Liaoning Dingjide Petrochemical (603255.SS), Kamada (KMDA).
How has Monopar Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +8.9% against -14.1% for the median peer; over one year -7.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.